Taglich Brothers Initiates Coverage on MDxHealth SA

NEW YORK, NY--(Marketwired - May 09, 2016) - Taglich Brothers, Inc. announces it initiated coverage of MDxHealth SA (EURONEXT BRUSSELS: MDXH)(OTC: MDXHF).

MDxHealth, headquartered in Herstal, Belgium, was established in 2003. The company has developed noninvasive diagnostics based on epigenetics, which uses selected biomarkers to detect the presence of cancer and gauge the extent of its progress by analyzing a patients' tissue, blood or urine samples. Biomarkers are measurable structures or processes in the body that indicate the presence of a disease and, potentially, the effects of treatments for that disease.

MDx's lead product, ConfirmMDx, was launched in 2012. ConfirmMDx analyzes a biopsy tissue sample from suspected prostate cancer cases who have tested negative. As initial biopsies (as well as follow-up ones) can be inconclusive, repeat biopsies are frequently performed to verify or rule out a diagnosis of prostate cancer. ConfirmMDx can confirm a true negative biopsy, sparing the patient the ordeal and risks of unnecessary repeat biopsies. It can also identify cases of undetected cancer.

SelectMDx was launched in Europe in 2015 and in the US in March 2016. SelectMDx, an initial diagnostic tool, analyzes a patient's urine and identifies patients at low risk for prostate cancer, as well as patients at high risk for undetected aggressive prostate cancer that should be treated with greater urgency.

MDx is also developing AssureMDx, a bladder cancer test, and is exploring diagnostics for kidney cancer. The company has developed markers for non-urologic -- colon, brain and cervical -- cancers that have been licensed to other diagnostic companies, adding royalties and milestone payments to its potential revenue stream.

As non-invasive and inexpensive diagnostics, ConfirmMDx and SelectMDx could significantly reduce the cost of prostate cancer diagnosis by enabling patients to avoid biopsies -- they cost the US healthcare system around $4 billion annually -- and improve outcomes by identifying cases of potentially lethal fast growing disease more quickly.

The complete 17-page report is available at www.taglichbrothers.com.

We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from Compliance. As of the date of this report no Taglich Brothers, Inc. employees had a position in the stock of the company mentioned in this report.

All research issued by Taglich Brothers, Inc. is based on public information. The company will pay to Taglich Brothers, Inc. the sum of US$1,500 per month for the production and dissemination of research reports for a period of at least six months after the initial research report on MDxHealth SA is published.

For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.